Loading...

Dedicated Peptide Lab And Global Facilities Will Unlock Biopharma Potential

Published
17 Dec 24
Updated
01 May 25
n/a
n/a
AnalystConsensusTarget's Fair Value
n/a
Loading
1Y
-23.1%
7D
2.7%

Author's Valuation

₹715.637.2% undervalued intrinsic discount

AnalystConsensusTarget Fair Value

Shared on 01 May 25

Fair value Decreased 17%

Shared on 23 Apr 25

Fair value Decreased 0.31%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 17 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 09 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 02 Apr 25

Fair value Increased 2.58%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 26 Mar 25

Fair value Decreased 0.58%

AnalystConsensusTarget has decreased profit margin from 16.3% to 14.4%.

Shared on 19 Mar 25

Fair value Increased 18%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 12 Mar 25